Cambridge technology company, HEALX, which integrates Artificial Intelligence (AI) with Drug Discovery to develop breakthrough treatments for rare diseases, announces the appointment of Kate Hilyard as chief operating officer (COO).
“Kate’s track record of scientific and business leadership includes over 25 years’ drug discovery experience in the pharma and biotech sector, with a decade finding new treatments for rare diseases. She joins from CHARLES RIVER where she was Corporate Vice President Discovery, leading and integrating multiple sites in the UK, EU and US working with a global client base. Previously she has held senior leadership roles at BIOFOCUS DPI Ltd (which was acquired by Charles River) and CAMBRIDGE ANTIBODY TECHNOLOGY (now part of MEDIMMUNE), having commenced her industry career at ROCHE. She gained her PhD in molecular immunology from Oxford University and her early academic career includes postdoctoral research in human biology at Oxford and Harvard Universities.”